Sean Maduck Sells 3,664 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Posted by Brenda Bartman on Aug 20th, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Sean Maduck sold 3,664 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $114.49, for a total value of $419,491.36. Following the completion of the transaction, the insider owned 9,755 shares of the company’s stock, valued at approximately $1,116,849.95. This trade represents a 27.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Sean Maduck also recently made the following trade(s):

On Monday, August 10th, Sean Maduck sold 1,031 shares of Corcept Therapeutics stock. The shares were sold at an average price of $114.52, for a total value of $118,070.12.
On Monday, August 3rd, Sean Maduck sold 20,305 shares of Corcept Therapeutics stock. The stock was sold at an average price of $114.70, for a total value of $2,328,983.50.
On Wednesday, July 1st, Sean Maduck sold 25,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $88.35, for a total value of $2,208,750.00.
On Monday, June 1st, Sean Maduck sold 25,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $70.21, for a total transaction of $1,755,250.00.
On Wednesday, May 27th, Sean Maduck sold 75,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $65.59, for a total transaction of $4,919,250.00.

Corcept Therapeutics Trading Up 0.8%

Shares of CORT opened at $119.02 on Thursday. The company’s fifty day simple moving average is $95.84 and its 200-day simple moving average is $63.62. The company has a market cap of $12.87 billion, a P/E ratio of 283.39 and a beta of 0.45. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $122.21.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The firm had revenue of $256.15 million during the quarter, compared to analysts’ expectations of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The firm’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.29 EPS. Analysts predict that Corcept Therapeutics Incorporated will post 1.13 earnings per share for the current fiscal year.

Institutional Trading of Corcept Therapeutics

A number of large investors have recently modified their holdings of CORT. Torren Management LLC purchased a new position in Corcept Therapeutics during the 4th quarter worth $25,000. Advisory Services Network LLC bought a new stake in Corcept Therapeutics during the 3rd quarter valued at $25,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Corcept Therapeutics in the 2nd quarter worth $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Corcept Therapeutics in the 4th quarter worth $31,000. Finally, State of Wyoming grew its position in shares of Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after buying an additional 186 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. UBS Group set a $135.00 price target on Corcept Therapeutics in a report on Thursday, May 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Piper Sandler reissued an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Finally, HC Wainwright upped their price target on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.17.

Read Our Latest Report on CORT

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.